<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2024-9.1.11</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4604</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group></article-categories><title-group><article-title>Посткастрационный синдром: актуальность, влияние на качество жизни, методы коррекции</article-title><trans-title-group xml:lang="en"><trans-title>Post-castration syndrome: relevance, impact on quality of life, methods of correction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5474-1080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зиганшин</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Ziganshin</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зиганшин Айдар Миндиярович – доктор медицинских наук, доцент кафедры акушерства и гинекологии с курсом ИДПО, </p><p>450008, г. Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Lenina str. 3, Ufa 450008</p></bio><email xlink:type="simple">zigaidar@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3887-1330</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тагиров</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tagirov</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тагиров Максим Рустамович – студент, </p><p>450008, г. Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Lenina str. 3, Ufa 450008</p></bio><email xlink:type="simple">maxim.tagirov00@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4153-5402</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабоян</surname><given-names>Д. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Baboyan</surname><given-names>D. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабоян Дохик Оганесовна – студентка, </p><p>450008, г. Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Lenina str. 3, Ufa 450008</p></bio><email xlink:type="simple">dokhik@icloud.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>9</volume><issue>1</issue><fpage>107</fpage><lpage>115</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зиганшин А.М., Тагиров М.Р., Бабоян Д.О., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Зиганшин А.М., Тагиров М.Р., Бабоян Д.О.</copyright-holder><copyright-holder xml:lang="en">Ziganshin A.M., Tagirov M.R., Baboyan D.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4604">https://www.actabiomedica.ru/jour/article/view/4604</self-uri><abstract><p>Аспекты современной медицины охватывают огромное количество заболеваний, в том числе посткастрационный синдром, возникающий в результате эндокринной дисфункции яичек у мужчин. Актуальность данного состояния велика, так как она возникает вследствие многих причин и является основанием для неполноценной жизни у мужчин. В обзоре показано влияние данного заболевания на качество жизни и методы его терапии. При написании данного обзора были использованы данные о  методах кастрации и её коррекции по материалам, опубликованным в базах eLibrary и PubMed. Поиск проводился по ключевым словам: «кастрация», «посткастрационный синдром», «рак предстательной железы». При  кастрации наблюдается снижение уровня тестостерона в сыворотке, так как андрогены стимулируют рост рака предстательной железы. На сегодня гормональная терапия является альтернативой кастрации при лечении пациентов с раком предстательной железы. Хирургическая кастрация является «золотым стандартом»; с её помощью можно подавить пролиферацию опухолевых клеток и индуцировать апоптоз опухоли, но она вызывает значительные нарушения качества жизни. В материале представлены характеристика лекарственных препаратов, показания, противопоказания и  побочные эффекты от проводимой гормональной терапии. Качество жизни мужчин с дефицитом тестостерона клинически связано с развитием метаболического синдрома, проявляющимся ожирением, стеатозом печени и сахарным диабетом 2-го типа. Многочисленные исследования отечественных и зарубежных учёных подтверждают влияние кастрации у мужчин на организм, при котором повышается риск развития инсульта, депрессии, когнитивных расстройств и болезни Альцгеймера. Таким образом, несмотря на значительные успехи современной медицины в терапии злокачественных заболеваний предстательной железы посткастрационный синдром остаётся до конца не изученной проблемой, что свидетельствует о необходимости дальнейшего изучения и разработки эффективных средств терапии.</p></abstract><trans-abstract xml:lang="en"><p>Aspects of  modern medicine cover a  huge number of  diseases, including postcastration syndrome, which occurs as a result of endocrine testicular dysfunction in men. The relevance of this condition is great, since it is caused by many reasons and is the basis for an inferior life in men. The review shows the impact of this disease on the quality of life and the methods for its treatment. When writing this review, we used data on castration methods and its correction based on materials published in the eLibrary and PubMed databases. The search was carried out using the keywords: “castration”, “post-castration syndrome”, “prostate cancer”. With castration, there is a decrease in serum testosterone levels, as androgens stimulate the growth of prostate cancer. Today, hormone therapy is an alternative to castration in the treatment of prostate cancer. Surgical castration is the gold standard; it can suppress tumor cell proliferation and induce tumor apoptosis, but it causes significant impairment of  quality of  life. The  article presents characteristics of  medications, indications, contraindications and side effects of hormone therapy. The quality of life of men with testosterone deficiency is clinically associated with the development of metabolic syndrome, manifested by obesity, hepatic steatosis and type 2 diabetes mellitus. Numerous studies by domestic and foreign scientists confirm the effect of castration in men on their body, which increases the risk of stroke, depression, cognitive disorders and Alzheimer’s disease. Thus, despite the significant advances of modern medicine in the treatment of malignant diseases of prostate, post-castration syndrome remains a completely unexplored problem, which indicates the need for further study and the development of effective therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>рак яичка</kwd><kwd>орхиэктомия</kwd><kwd>посткастрационный синдром</kwd><kwd>кастрация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>testicular cancer</kwd><kwd>orchiectomy</kwd><kwd>post-castration syndrome</kwd><kwd>castration</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Пушкарь Д.Ю., Говоров А.В., Васильев А.О., Колонтарев К.Б., Прилепская Е.А., Ковылина М.В., и др. Московская программа ранней диагностики и лечения рака предстательной железы. Проблемы социальной гигиены, здравоохранения и истории медицины. 2019; 27(Спецвып.): 677-686. doi: 10.32687/0869-866X-2019-27-si1-677-686</mixed-citation><mixed-citation xml:lang="en">Pushkar DY, Govorov  AV, Vasilyev  AO, Kolontarev  KB, Prilepskaya  EA, Kovylina MV, et al. Moscow program of early detection and treatment of  prostate cancer. Problems of  Social Hygiene, Public Health and  History of Medicine. 2019; 27(Spec.  Iss.): 677-686. (In  Russ.). doi: 10.32687/0869-866X-2019-27-si1-677-686</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361. doi: 10.1101/cshperspect.a030361</mixed-citation><mixed-citation xml:lang="en">Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361. doi: 10.1101/cshperspect.a030361</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022; 43(6): 1003-1037. doi: 10.1210/endrev/bnac010</mixed-citation><mixed-citation xml:lang="en">Melmed  S, Kaiser  UB, Lopes  MB, Bertherat  J, Syro  LV, Raverot G, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022; 43(6): 1003-1037. doi: 10.1210/endrev/bnac010</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal A, Dayal A, Kircher SM, Chen RC, Royce TJ. Analysis of price transparency via National Cancer Institute-designated cancer centers’ chargemasters for prostate cancer radiation therapy. JAMA Oncol. 2020; 6(3): 409-412. doi: 10.1001/jamaoncol.2019.5690</mixed-citation><mixed-citation xml:lang="en">Agarwal A, Dayal A, Kircher SM, Chen RC, Royce TJ. Analysis of  price transparency via  National Cancer Institute-designated cancer centers’ chargemasters for  prostate cancer radiation therapy. JAMA Oncol. 2020; 6(3): 409-412. doi: 10.1001/jamaoncol.2019.5690</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Grigorian A, Livingston JK, Schubl SD, Hasjim BJ, Mayers D, Kuncir E, et al. National analysis of testicular and scrotal trauma in the USA. Res Rep Urol. 2018; 10: 51-56. doi: 10.2147/RRU.S172848</mixed-citation><mixed-citation xml:lang="en">Grigorian  A, Livingston  JK, Schubl  SD, Hasjim  BJ, Mayers D, Kuncir E, et al. National analysis of testicular and scrotal trauma in the USA. Res Rep Urol. 2018; 10: 51-56. doi: 10.2147/RRU.S172848</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bizic MR, Jeftovic M, Pusica S, Stojanovic B, Duisin D, Vujovic S, et al. Gender dysphoria: Bioethical aspects of medical treatment. Biomed Res Int. 2018; 2018: 9652305. doi: 10.1155/2018/9652305</mixed-citation><mixed-citation xml:lang="en">Bizic  MR, Jeftovic  M, Pusica  S, Stojanovic  B, Duisin  D, Vujovic  S, et  al. Gender dysphoria: Bioethical aspects of  medical treatment. Biomed Res Int. 2018; 2018: 9652305. doi: 10.1155/2018/9652305</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tollinche LE, Walters CB, Radix A, Long M, Galante L, Goldstein ZG, et al. The perioperative care of the transgender patient. Anesth Analg. 2018; 127(2): 359-366. doi: 10.1213/ANE.0000000000003371</mixed-citation><mixed-citation xml:lang="en">Tollinche  LE, Walters  CB, Radix  A, Long  M, Galante  L, Goldstein  ZG, et  al. The  perioperative care of  the  transgender patient. Anesth Analg. 2018; 127(2): 359-366. doi:  10.1213/ANE.0000000000003371</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Salas-Humara C, Sequeira GM, Rossi W, Dhar CP. Gender affirming medical care of transgender youth. Curr Probl Pediatr Adolesc Health Care. 2019; 49(9): 100683. doi: 10.1016/j.cppeds.2019.100683</mixed-citation><mixed-citation xml:lang="en">Salas-Humara C, Sequeira GM, Rossi W, Dhar CP. Gender affirming medical care of  transgender youth. Curr Probl Pediatr Adolesc Health Care. 2019; 49(9): 100683. doi:  10.1016/j.cppeds.2019.100683</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobsen FM, Rudlang TM, Fode M, Østergren PB, Sønksen J, Ohl DA, et al. The impact of testicular torsion on testicular function. World J Mens Health. 2020; 38(3): 298-307. doi: 10.5534/wjmh.190037</mixed-citation><mixed-citation xml:lang="en">Jacobsen FM, Rudlang TM, Fode M, Østergren PB, Sønksen J, Ohl DA, et al. The impact of testicular torsion on testicular function. World J Mens Health. 2020; 38(3): 298-307. doi: 10.5534/wjmh.190037</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shin J, Jeon GW. Comparison of diagnostic and treatment guidelines for undescended testis. Clin Exp Pediatr. 2020; 63(11): 415-421. doi: 10.3345/cep.2019.01438</mixed-citation><mixed-citation xml:lang="en">Shin J, Jeon GW. Comparison of diagnostic and treatment guidelines for undescended testis. Clin Exp Pediatr. 2020; 63(11): 415-421. doi: 10.3345/cep.2019.01438</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C, et al. Risk factors for cryptorchidism. Nat Rev Urol. 2017; 14(9): 534-548. doi: 10.1038/nrurol.2017.90</mixed-citation><mixed-citation xml:lang="en">Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C, et al. Risk factors for cryptorchidism. Nat Rev Urol. 2017; 14(9): 534-548. doi: 10.1038/nrurol.2017.90</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Steele CB, Li J, Huang B, Weir HK. Prostate cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer. 2017; 123(Suppl 24): 5160- 5177. doi: 10.1002/cncr.31026</mixed-citation><mixed-citation xml:lang="en">Steele  CB, Li  J, Huang  B, Weir  HK. Prostate cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer. 2017; 123(Suppl 24): 5160- 5177. doi: 10.1002/cncr.31026</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7: F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1</mixed-citation><mixed-citation xml:lang="en">Ritch C, Cookson M. Recent trends in the management of  advanced prostate cancer. F1000Res. 2018; 7: F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur Urol. 2019; 76(1): 115-124. doi: 10.1016/j.eururo.2019.02.003</mixed-citation><mixed-citation xml:lang="en">Burdett  S, Boevé  LM, Ingleby  FC, Fisher  DJ, Rydzewska  LH, Vale  CL, et  al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur Urol. 2019; 76(1): 115-124. doi: 10.1016/j.eururo.2019.02.003</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Itty S, Getzenberg RH. How do we define “castration” in men on androgen deprivation therapy? Asian J Androl. 2020; 22(5): 441-446. doi: 10.4103/aja.aja_139_19</mixed-citation><mixed-citation xml:lang="en">Itty S, Getzenberg RH. How do we define “castration” in men on androgen deprivation therapy? Asian  J Androl. 2020; 22(5): 441-446. doi: 10.4103/aja.aja_139_19</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-1177. doi: 10.1016/S0140-6736(15)01037-5</mixed-citation><mixed-citation xml:lang="en">James ND, Sydes  MR, Clarke  NW, Mason  MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or  both to  first-line long-term hormone therapy in  prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-1177. doi: 10.1016/S0140-6736(15)01037-5</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial. J Clin Oncol. 2016; 34(18): 2098-2106. doi: 10.1200/JCO.2015.64.9285</mixed-citation><mixed-citation xml:lang="en">Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial. J Clin Oncol. 2016; 34(18): 2098-2106. doi: 10.1200/JCO.2015.64.9285</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castrationresistant prostate cancer. N Engl J Med. 2018; 378(26): 2465-2474. doi: 10.1056/NEJMoa1800536</mixed-citation><mixed-citation xml:lang="en">Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castrationresistant prostate cancer. N Engl J Med. 2018; 378(26): 2465-2474. doi: 10.1056/NEJMoa1800536</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yecies T, Bandari J, Schneck F, Cannon G. Direction of rotation in testicular torsion and identification of predictors of testicular salvage. Urology. 2018; 114: 163-166. doi: 10.1016/j.urology.2017.11.034</mixed-citation><mixed-citation xml:lang="en">Yecies T, Bandari  J, Schneck  F, Cannon  G. Direction of  rotation in  testicular torsion and  identification of  predictors of  testicular salvage. Urology. 2018; 114: 163-166. doi:  10.1016/j.urology.2017.11.034</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Mellick LB, Sinex JE, Gibson RW, Mears K. A systematic review of testicle survival time after a torsion event. Pediatr Emerg Care. 2019; 35(12): 821-825. doi: 10.1097/PEC.0000000000001287</mixed-citation><mixed-citation xml:lang="en">Mellick  LB, Sinex  JE, Gibson  RW, Mears  K. A  systematic review of testicle survival time after a torsion event. Pediatr Emerg Care. 2019; 35(12): 821-825. doi: 10.1097/PEC.0000000000001287</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018; 73(6): 847-855. doi: 10.1016/j.eururo.2018.02.001</mixed-citation><mixed-citation xml:lang="en">Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018; 73(6): 847-855. doi: 10.1016/j.eururo.2018.02.001</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D, et al. Hormonal treatment and quality of life of prostate cancer patients: New evidence. Minerva Urol Nefrol. 2018; 70(2): 144-151. doi: 10.23736/S0393-2249.17.03066-1</mixed-citation><mixed-citation xml:lang="en">Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D, et al. Hormonal treatment and quality of life of prostate cancer patients: New evidence. Minerva Urol Nefrol. 2018; 70(2): 144-151. doi: 10.23736/S0393-2249.17.03066-1</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. Eur Urol. 2019; 75(3): 410-418. doi: 10.1016/j.eururo.2018.09.008</mixed-citation><mixed-citation xml:lang="en">Boevé  LMS, Hulshof  MCCM, Vis  AN, Zwinderman  AH, Twisk  JWR, Witjes WPJ, et  al. Effect on  survival of  androgen deprivation therapy alone compared to  androgen deprivation therapy combined with  concurrent radiation therapy to  the  prostate in  patients with  primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from  the  HORRAD trial. Eur Urol. 2019; 75(3): 410-418. doi: 10.1016/j.eururo.2018.09.008</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018; 29(5): 1249-1257. doi: 10.1093/annonc/mdy071</mixed-citation><mixed-citation xml:lang="en">Vale  CL, Fisher  DJ, White  IR, Carpenter  JR, Burdett  S, Clarke NW, et al. What is the optimal systemic treatment of men with  metastatic, hormone-naive prostate cancer? A  STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018; 29(5): 1249-1257. doi: 10.1093/annonc/mdy071</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Srivatsav A, Balasubramanian A, Butaney M, Thirumavalavan N, McBride JA, Gondokusumo J, et al. Patient attitudes toward testicular prosthesis placement after orchiectomy. Am J Mens Health. 2019; 13(4): 1557988319861019. doi: 10.1177/1557988319861019</mixed-citation><mixed-citation xml:lang="en">Srivatsav  A, Balasubramanian  A, Butaney  M, Thirumavalavan  N, McBride  JA, Gondokusumo  J, et  al. Patient attitudes toward testicular prosthesis placement after  orchiectomy. Am J Mens Health. 2019; 13(4): 1557988319861019. doi: 10.1177/1557988319861019</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson E, Pascoe C, Sathianathen N, Katz D, Murphy D, Lawrentschuk N. Subinguinal orchiectomy – A minimally invasive approach to open surgery. BJUI Compass. 2020; 1(5): 160-164. doi: 10.1002/bco2.33</mixed-citation><mixed-citation xml:lang="en">Anderson E, Pascoe C, Sathianathen N, Katz D, Murphy D, Lawrentschuk N. Subinguinal orchiectomy – A minimally invasive approach to  open surgery. BJUI Compass. 2020; 1(5): 160-164. doi: 10.1002/bco2.33</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford TG, Burg ML, Hu B, Loh-Doyle J, Hugen CM, Cai J, et al. Satisfaction with testicular prosthesis after radical orchiectomy. Urology. 2018; 114: 128-132. doi: 10.1016/j.urology.2017.12.006</mixed-citation><mixed-citation xml:lang="en">Clifford TG, Burg  ML, Hu  B, Loh-Doyle  J, Hugen  CM, Cai  J, et  al. Satisfaction with  testicular prosthesis after  radical orchiectomy. Urology. 2018; 114: 128-132. doi:  10.1016/j.urology.2017.12.006</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Baird DC, Meyers GJ, Hu JS. Testicular cancer: Diagnosis and treatment. Am Fam Physician. 2018; 97(4): 261-268.</mixed-citation><mixed-citation xml:lang="en">Baird DC, Meyers GJ, Hu JS. Testicular cancer: Diagnosis and treatment. Am Fam Physician. 2018; 97(4): 261-268.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Elenkov A, Giwercman A. Testicular dysfunction among cancer survivors. Endocrinol Metab Clin North Am. 2022; 51(1): 173-186. doi: 10.1016/j.ecl.2021.11.014</mixed-citation><mixed-citation xml:lang="en">Elenkov A, Giwercman A. Testicular dysfunction among cancer survivors. Endocrinol Metab Clin North Am. 2022; 51(1): 173-186. doi: 10.1016/j.ecl.2021.11.014</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Leone G, Tucci M, Buttigliero C, Zichi C, Pignataro D, Bironzo P, et al. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocr Relat Cancer. 2018; 25(1): R1-R9. doi: 10.1530/ERC-17-0355</mixed-citation><mixed-citation xml:lang="en">Leone  G, Tucci  M, Buttigliero  C, Zichi  C, Pignataro  D, Bironzo  P, et  al. Antiandrogen withdrawal syndrome (AAWS) in  the  treatment of  patients with  prostate cancer. Endocr Relat Cancer. 2018; 25(1): R1-R9. doi: 10.1530/ERC-17-0355</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Scialpi M, Improta A, Carpini DD, Tonto M, Nicola R, Mancioli F. Biparametric magnetic resonance imaging in the surveillance of testicular tumors following radical orchiectomy. Turk JUrol. 2020; 46(6): 436-441. doi: 10.5152/tud.2020.20353</mixed-citation><mixed-citation xml:lang="en">Scialpi M, Improta A, Carpini DD, Tonto M, Nicola R, Mancioli F. Biparametric magnetic resonance imaging in the surveillance of testicular tumors following radical orchiectomy. Turk JUrol. 2020; 46(6): 436-441. doi: 10.5152/tud.2020.20353</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hana T, Raveendran L, Grober E, Potter E, Blodgett N, Krakowsky Y. Initial clinical experience with simple orchiectomy procedures in the context of transition-related surgeries. Int J Transgend Health. 2020; 21(4): 403-409. doi: 10.1080/26895269.2020.1774030</mixed-citation><mixed-citation xml:lang="en">Hana T, Raveendran L, Grober E, Potter E, Blodgett N, Krakowsky Y. Initial clinical experience with simple orchiectomy procedures in the context of transition-related surgeries. Int J Transgend Health. 2020; 21(4): 403-409. doi: 10.1080/26895269.2020.1774030</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Canner JK, Harfouch O, Kodadek LM, Pelaez D, Coon D, Offodile AC 2nd, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018; 153(7): 609-616. doi: 10.1001/jamasurg.2017.6231</mixed-citation><mixed-citation xml:lang="en">Canner JK, Harfouch O, Kodadek LM, Pelaez D, Coon D, Offodile AC 2nd, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018; 153(7): 609-616. doi: 10.1001/jamasurg.2017.6231</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Orakwe DE, Tijani KH, Jeje EA, Ogunjimi MA, Rufus WO, Alabi TO. Bilateral subcapsular orchiectomy versus bilateral total orchiectomy: Comparison of the quality of life post-orchiectomy. Niger Postgrad Med J. 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17</mixed-citation><mixed-citation xml:lang="en">Orakwe DE, Tijani KH, Jeje EA, Ogunjimi MA, Rufus WO, Alabi TO. Bilateral subcapsular orchiectomy versus bilateral total orchiectomy: Comparison of the quality of life post-orchiectomy. Niger Postgrad Med J. 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Topuz B, Sarıkaya S, Korkmaz C, Baykal B, Kaya E, Ebiloğlu T, et al. Examination of clinical data and semen analysis results of patients undergoing orchiectomy for testicular tumor. Rev Assoc Med Bras (1992). 2021; 67(4): 577-584. doi: 10.1590/1806-9282.20201096</mixed-citation><mixed-citation xml:lang="en">Topuz  B, Sarıkaya  S, Korkmaz  C, Baykal  B, Kaya  E, Ebiloğlu T, et al. Examination of clinical data and semen analysis results of patients undergoing orchiectomy for testicular tumor. Rev Assoc Med Bras (1992). 2021; 67(4): 577-584. doi: 10.1590/1806-9282.20201096</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Kajitani N, Takahashi J, Honda H, Hamahara J, Ando S. Severe visceral obesity, fatty liver and diabetes after orchiectomy for prostate cancer. Intern Med. 2020; 59(18): 2281-2285. doi: 10.2169/internalmedicine.4653-20</mixed-citation><mixed-citation xml:lang="en">Kajitani  N, Takahashi  J, Honda  H, Hamahara  J, Ando  S. Severe visceral obesity, fatty liver and  diabetes after  orchiectomy for  prostate cancer. Intern Med. 2020; 59(18): 2281-2285. doi: 10.2169/internalmedicine.4653-20</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Baik M, Jeong JY, Park SJ, Yoo SP, Lee JO, Lee JS, et al. Testosterone deficiency caused by castration increases adiposity in male rats in a tissue-specific and diet-dependent manner. Genes Nutr. 2020; 15(1): 14. doi: 10.1186/s12263-020-00673-1</mixed-citation><mixed-citation xml:lang="en">Baik M, Jeong  JY, Park  SJ, Yoo  SP, Lee  JO, Lee  JS, et  al. Testosterone deficiency caused by castration increases adiposity in male rats in a tissue-specific and diet-dependent manner. Genes Nutr. 2020; 15(1): 14. doi: 10.1186/s12263-020-00673-1</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Robert J, Gomes FE, Porter I, Sumner JP. Orbital apex syndrome secondary to an orbital sarcoma in a dog. Can Vet J. 2021; 62(1): 27-31.</mixed-citation><mixed-citation xml:lang="en">Robert  J, Gomes  FE, Porter  I, Sumner  JP. Orbital apex syndrome secondary to  an  orbital sarcoma in  a  dog. Can Vet J. 2021; 62(1): 27-31.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019; 37(32): 2974-2986. doi: 10.1200/JCO.19.00799</mixed-citation><mixed-citation xml:lang="en">Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of  androgen deprivation therapy with  enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019; 37(32): 2974-2986. doi:  10.1200/JCO.19.00799</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers (Basel). 2021; 13(2): 334. doi: 10.3390/cancers13020334</mixed-citation><mixed-citation xml:lang="en">Bansal D, Reimers  MA, Knoche  EM, Pachynski  RK. Immunotherapy and  immunotherapy combinations in  metastatic castration-resistant prostate cancer. Cancers (Basel). 2021; 13(2): 334. doi: 10.3390/cancers13020334</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nat Commun. 2019; 10(1): 207. doi: 10.1038/s41467-018-08170-1</mixed-citation><mixed-citation xml:lang="en">Zaorsky  NG, Zhang Y, Tuanquin  L, Bluethmann  SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nat Commun. 2019; 10(1): 207. doi: 10.1038/s41467-018-08170-1</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">McFarland DC, Walsh L, Napolitano S, Morita J, Jaiswal R. Suicide in Patients with cancer: Identifying the risk factors. Oncology (Williston Park). 2019; 33(6): 221-6.</mixed-citation><mixed-citation xml:lang="en">McFarland DC, Walsh L, Napolitano S, Morita J, Jaiswal R. Suicide in Patients with cancer: Identifying the risk factors. Oncology (Williston Park). 2019; 33(6): 221-6.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019; 22(1): 24-38. doi: 10.1038/s41391-018-0079-0</mixed-citation><mixed-citation xml:lang="en">Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo  ACL, Mendoza-Valdes  A, et  al. Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019; 22(1): 24-38. doi: 10.1038/s41391-018-0079-0</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020; 78(3): 347-357. doi: 10.1016/j.eururo.2020.04.061</mixed-citation><mixed-citation xml:lang="en">Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020; 78(3): 347-357. doi: 10.1016/j.eururo.2020.04.061</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021; 16(7): e0255239. doi: 10.1371/journal.pone.0255239</mixed-citation><mixed-citation xml:lang="en">Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021; 16(7): e0255239. doi: 10.1371/journal.pone.0255239</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018; 102(2): 199-214. doi: 10.1016/j.mcna.2017. 11.001</mixed-citation><mixed-citation xml:lang="en">Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018; 102(2): 199-214. doi: 10.1016/j.mcna.2017. 11.001</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019; 70: 479-499. doi: 10.1146/annurev-med-051517-011947</mixed-citation><mixed-citation xml:lang="en">Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019; 70: 479-499. doi: 10.1146/annurev-med-051517-011947</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Bandarkar AN, Blask AR. Testicular torsion with preserved flow: Key sonographic features and value-added approach to diagnosis. Pediatr Radiol. 2018; 48(5): 735-744. doi: 10.1007/ s00247-018-4093-0</mixed-citation><mixed-citation xml:lang="en">Bandarkar AN, Blask AR. Testicular torsion with preserved flow: Key sonographic features and  value-added approach to  diagnosis. Pediatr Radiol. 2018; 48(5): 735-744. doi:  10.1007/ s00247-018-4093-0</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Sindhu II, Noor N, Mansoor R. Choriocarcinoma syndrome: A rare presentation of testicular germ cell tumour. J Pak Med Assoc. 2021; 71(8): 2090-2092. doi: 10.47391/ JPMA.234</mixed-citation><mixed-citation xml:lang="en">Sindhu II, Noor N, Mansoor R. Choriocarcinoma syndrome: A  rare presentation of  testicular germ cell tumour. J Pak Med Assoc. 2021; 71(8): 2090-2092. doi:  10.47391/ JPMA.234</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
